Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics and keeping the price target at $25.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Francois Brisebois has given his Buy rating due to a combination of factors related to nomlabofusp’s risk‑benefit profile and market potential. Surveyed U.S. neurologists and cardiologists who regularly treat Friedreich’s ataxia indicated that the anaphylaxis signal, while notable, is generally seen as manageable with proper mitigation strategies, and could improve further in the ongoing trial focused on treatment‑naïve patients, especially given the severe, life‑shortening nature of the disease.
In addition, physicians expressed strong confidence in nomlabofusp’s efficacy, citing compelling frataxin replacement data in skin and encouraging clinical outcomes that they believe can translate into meaningful neurological and cardiac benefits in real‑world practice. Combined with the upcoming 2Q26 topline readout, the planned June 2026 BLA filing for accelerated approval, and the substantial unmet need in Friedreich’s ataxia, Brisebois views the therapy as having significant commercial upside that supports a Buy recommendation on LRMR.
According to TipRanks, Brisebois is a 2-star analyst with an average return of 0.1% and a 38.26% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Tarsus Pharmaceuticals, and Aquestive Therapeutics.
In another report released on March 20, Citi also reiterated a Buy rating on the stock with a $14.00 price target.